Clinical Monitoring During Ketamine Administration: Assessment Protocols

Clinical monitoring during ketamine administration means tracking a patient's cardiovascular, neuropsychiatric, and cognitive response before, during, and after each dose, using standardized rating scales and defined intervention thresholds. Many outpatient programs start this process with a clinical online medical assessment for ketamine candidates, using telehealth intake and structured questionnaires to screen out contraindications before any dose is given in person. This two-part model, an online medical assessment for screening plus in-person monitoring for administration, is becoming the standard framework for outpatient ketamine therapy.

No single monitoring standard exists across the field. The American Society of Anesthesiologists (ASA), American Psychiatric Association (APA), and American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3) each publish guidance that differs in scope and specificity (Sanacora et al., 2017). Understanding what a thorough monitoring protocol actually includes helps patients know what to expect and helps clinics evaluate their own practices.

Pre-Treatment Screening and Online Medical Assessment

Before any dose is given, clinicians complete a structured screening that identifies contraindications and sets baseline values. This typically happens through an online medical assessment or telehealth intake visit combined with in-person vitals and labs. Our telehealth ketamine protocols guide covers how remote intake fits into a full treatment plan.

Standard pre-treatment screening covers:

• Cardiovascular history and resting blood pressure. Uncontrolled hypertension above 180/100 mmHg is a relative contraindication because of ketamine's stimulant effect on heart rate and blood pressure (Cohen et al., 2018).
• Baseline liver function tests (ALT, AST, GGT, bilirubin) to identify pre-existing hepatic dysfunction.
• Psychiatric evaluation for active psychosis or uncontrolled substance use disorder, both generally treated as contraindications (Sanacora et al., 2017).
• Pregnancy testing for patients who could become pregnant, given limited safety data on ketamine in pregnancy.
• Baseline symptom scores using validated tools such as the MADRS or PHQ-9 for depression, the C-SSRS for suicidal ideation, and the GAD-7 for anxiety.

These baseline numbers become the reference point for judging whether treatment is working and for catching problems later. Our drug interactions guide covers medications that can complicate ketamine screening and dosing decisions.

Monitoring During Administration

Ketamine raises blood pressure and heart rate through central sympathetic activation, so hemodynamic checks are the backbone of in-session monitoring. Standard practice includes blood pressure and heart rate readings every 15 minutes during an IV infusion, continuous pulse oximetry, and ECG monitoring for patients with known cardiac risk factors. According to the American Society of Anesthesiologists' standards for basic anesthetic monitoring, continuous oxygenation monitoring is part of the standard of care for procedures involving sedation, since it can flag a drop in oxygen saturation before it becomes clinically significant.

Dissociative symptoms are the most characteristic subjective effect of sub-anesthetic ketamine. The Clinician-Administered Dissociative States Scale (CADSS), a 23-item tool covering depersonalization, derealization, and amnesia, is the most widely used instrument for tracking this (Bremner et al., 1998). It is typically scored at baseline, near peak drug effect around 40 minutes into a standard infusion, and again 60 to 90 minutes after infusion ends to confirm the patient has returned to baseline. Most patients recover within 90-120 minutes; symptoms lasting beyond two hours are atypical and warrant closer evaluation. Nausea is also common, affecting roughly 10-30% of patients on sub-anesthetic infusions, and many clinics give an antiemetic before treatment to reduce this risk. Our common side effects guide covers what patients typically experience during and after a session.

Long-Term Monitoring for Repeated Treatment

Patients on maintenance ketamine need periodic safety checks beyond single-session monitoring. Liver function tests are repeated every three to six months, since chronic exposure has been linked to hepatotoxicity in case reports (Lo et al., 2022); a transaminase level above three times the upper limit of normal warrants pausing treatment and a hepatology referral. Urinary symptoms, including frequency, urgency, and pain, are screened every three to six months with a tool such as the International Prostate Symptom Score, since chronic high-dose ketamine use is associated with lower urinary tract symptoms and, in severe cases, cystitis (Middela and Pearce, 2011). Programs offering ongoing treatment should also repeat brief cognitive screening every six to twelve months and use tools such as the DAST-10 to watch for signs of misuse. Adverse events can also be reported through the FDA's MedWatch program, the agency's system for tracking safety issues with drugs already on the market. Our safety and side effects guide covers what these risks look like over the course of ongoing treatment.